These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19529761)

  • 21. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
    Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of community level treatment and preventative interventions on trachoma prevalence in rural Ethiopia.
    Cumberland P; Edwards T; Hailu G; Harding-Esch E; Andreasen A; Mabey D; Todd J
    Int J Epidemiol; 2008 Jun; 37(3):549-58. PubMed ID: 18356196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction and return of infectious trachoma in severely affected communities in Ethiopia.
    Lakew T; House J; Hong KC; Yi E; Alemayehu W; Melese M; Zhou Z; Ray K; Chin S; Romero E; Keenan J; Whitcher JP; Gaynor BD; Lietman TM
    PLoS Negl Trop Dis; 2009; 3(2):e376. PubMed ID: 19190781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II).
    Mahmud H; Haile BA; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Liu Z; Callahan EK; Cotter SY; Varnado NE; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Clin Infect Dis; 2023 Aug; 77(3):388-395. PubMed ID: 37021692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    Porco TC; Gebre T; Ayele B; House J; Keenan J; Zhou Z; Hong KC; Stoller N; Ray KJ; Emerson P; Gaynor BD; Lietman TM
    JAMA; 2009 Sep; 302(9):962-8. PubMed ID: 19724043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When the Neighboring Village is Not Treated: Role of Geographic Proximity to Communities Not Receiving Mass Antibiotics for Trachoma.
    Mosenia A; Haile BA; Shiferaw A; Gebresillasie S; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Callahan EK; Zhou Z; Lietman TM; Keenan JD
    Clin Infect Dis; 2023 Mar; 76(6):1038-1042. PubMed ID: 36477547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.
    Keenan JD; Ayele B; Gebre T; Moncada J; Stoller NE; Zhou Z; Porco TC; McCulloch CE; Gaynor BD; Emerson PM; Schachter J; Lietman TM
    Clin Infect Dis; 2012 Jan; 54(2):253-6. PubMed ID: 22095569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.
    Gower EW; Solomon AW; Burton MJ; Aguirre A; Muñoz B; Bailey R; Holland M; Makalo P; Massae P; Mkocha H; Mabey DC; West SK
    Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4767-71. PubMed ID: 17065486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass treatment with single-dose azithromycin for trachoma.
    Solomon AW; Holland MJ; Alexander ND; Massae PA; Aguirre A; Natividad-Sancho A; Molina S; Safari S; Shao JF; Courtright P; Peeling RW; West SK; Bailey RL; Foster A; Mabey DC
    N Engl J Med; 2004 Nov; 351(19):1962-71. PubMed ID: 15525721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial.
    Harding-Esch EM; Edwards T; Mkocha H; Munoz B; Holland MJ; Burr SE; Sillah A; Gaydos CA; Stare D; Mabey DC; Bailey RL; West SK;
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e861. PubMed ID: 21072224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia.
    Burr SE; Hart JD; Edwards T; Baldeh I; Bojang E; Harding-Esch EM; Holland MJ; Lietman TM; West SK; Mabey DC; Sillah A; Bailey RL
    PLoS Negl Trop Dis; 2013; 7(7):e2347. PubMed ID: 23936573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The distribution of the prevalence of ocular chlamydial infection in communities where trachoma is disappearing.
    Lietman TM; Gebre T; Abdou A; Alemayehu W; Emerson P; Blumberg S; Keenan JD; Porco TC
    Epidemics; 2015 Jun; 11():85-91. PubMed ID: 25979286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
    Yohannan J; He B; Wang J; Greene G; Schein Y; Mkocha H; Munoz B; Quinn TC; Gaydos C; West SK
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4144-50. PubMed ID: 24906862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mass treatment with azithromycin for trachoma control: participation clusters in households.
    Ssemanda EN; Munoz B; Harding-Esch EM; Edwards T; Mkocha H; Bailey RL; Sillah A; Stare D; Mabey DC; West SK;
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.